The cost of healthcare in general is a debilitating, pre-existing condition for Americans. But the high prices of prescription drugs usually stand out as a pain point. While there are many insidious reasons why Americans pay more—often far more—for their medicines than people in peer countries, exploitation of the US patent system is an obvious one.
A study published Monday in JAMA highlights just how much patent exploitation has grown since 1990. In that time, researchers found the number of patents on small-molecule drugs have more than tripled, going from an average of 2.1 patents per drug approved in 1990 to 6.9 for those approved in 2019.
Most of the growth was in “nonprimary” patents—patents that generally aren’t related to a drug’s active ingredient, but are instead for things like minor tweaks to a drug’s non-active ingredients, updates to the way the drug is used, or the design of specialty delivery devices, such as auto-injectors. Together, those extra patents on an individual drug can create what’s called a “patent thicket,” which delays the release of affordable generics on the market, keeping drug prices higher for longer without actual clinical advancements.
AMD acquires World Labs AI startup, upping the ante against Nvidia
September 29, 2026
Trump ads paid for by US government allegedly violate anti-propaganda laws
September 29, 2026
NASA has a Dragon dilemma, and there appear to be no good answers
September 29, 2026
Here's what actually happened in OpenAI's Australian gov't server hack
September 29, 2026
Apple pressured to explain Trump role in ICE-tracking app removals
September 29, 2026
This study looks at how and with whom connected cars share your data
September 29, 2026
Former American Idol contestant and pastor found guilty of murdering wife
September 29, 2026
More than 400 detained as France student protests escalate
September 29, 2026
AMD acquires World Labs AI startup, upping the ante against Nvidia
September 29, 2026
5 New Sites Added To India's UNESCO Tentative List For World Heritage
September 29, 2026
Trump rules out joint US-China venture to develop AI
September 29, 2026
Trump ads paid for by US government allegedly violate anti-propaganda laws
September 29, 2026